Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes

Blood Pressure

Volumn 15, Issue 5, 2006, Pages 268-274

  Grassi, Guido ^a,b,c   Quarti Trevano, Fosca ^a   Scopelliti, Francesco ^a   Seravalle, Gino ^a,b,c   Cuspidi, Cesare ^a   Mancia, Giuseppe ^a,b,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c Centro di Fisiologia Clinica e Ipertensione   (Italy)

Author keywords

Calcium channel blockers; Diuretics; Hydrochlorothiazide; Hypertension; Lercanidipine; Vascular hypertrophy

Indexed keywords

HYDROCHLOROTHIAZIDE; LERCANIDIPINE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPHYGMOMANOMETRY; VASCULAR RESISTANCE; VASCULARIZATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

BLOOD VESSELS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; DIHYDROPYRIDINES; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY; MALE; MIDDLE AGED; VASCULAR RESISTANCE;

EID: 33847225572     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050600963669     Document Type: Article

References (38)

1. Klingbeil, A. U., Schneider, M., Martus, P., Messerli, F. H. and Scmieder, R. E. (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med, 115, pp. 41-46.
2. Mancia, G. (2006) Role of outcome trials in providing information on antihypertensive treatment. Importance and limitations. Am J Hypertens, 19, pp. 1-7.
3. Otterstad, J. E., Smiseth, O. and Kjeldsen, S. E. (1996) Hypertensive left ventricular hypertrophy: Pathophysiology, assessment and treatment. Blood Press, 5, pp. 5-15.
4. Sivertsson, R. and Hansson, L. (1976) Effects of blood pressure reduction on the structural vascular abnormality in skin and muscle vascular beds in human essential hypertension. Clin Sci Mol Med, 3, pp. 77s-79s.
5. Sivertsson, R., Andersson, O. and Hansson, L. (1979) Blood pressure reduction and vascular adaptation. A study on long-term effects of treatment with mefruside or atenolol. Acta Med Scand, 205, pp. 477-482.
6. Svensson, A., Gudbrandsson, T., Sivertsson, R. and Hanson, L. (1982) Haemodynamic effects of metoprolol and pindolol: A comparison in hypertensive patients. Br J Clin Pharmacol, 13, pp. 259S-267S.
7. Giannattasio, C., Cléroux, J., Cuspidi, C., Sampieri, L., Stella, M. L. and Seravalle, G. (1993) Cardiac and vascular hypertrophy in essential hypertension. High Blood Press, 2, pp. 299-306.
8. Schiffrin, E. L., Deng, L. Y. and Larochelle, P. (1994) Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension, 23, pp. 83-91.
9. Thybo, N. K., Stephens, N., Cooper, A., Aalkjaer, C., Heagerty, A. M. and Mulvany, M. J. (1995) Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension, 25, pp. 474-481.
10. Kiowski, W., Linder, L., Nuesch, R. and Martina, B. (1996) Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension, 27, pp. 371-376.
11. Rizzoni, D., Muiesan, M. L., Porteri, E., Castellano, M., Zulli, R. and Bettoni, G. (1997) Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens, 15, pp. 197-204.
12. Marceau, M., Kouame, N., Lacourciere, Y. and Cleroux, J. (1998) Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy. J Hypertens, 16, pp. 673-679.
13. Schiffrin, E. L., Park, J. B., Intengan, H. D. and Toyuz, R. M. (2000) Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation, 101, pp. 1653-1659.
14. Rizzoni, D., Porteri, E., De Ciuceis, C., Sleiman, I., Rodella, L. and Rezzani, R. (2005) Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension, 45, pp. 659-665.
15. Olsen, M. H., Wachtell, K., Neland, K., Bella, J. N., Rokkedal, J. and Dige-Petersen, H. (2005) Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press, 14, pp. 177-183.
16. Dell'Omo, G., Penno, G., Pucci, L., Pellegrini, G., Scotti, A. and Prato, S. Del (2005) The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis, 16, pp. 67-73.
17. Agabiti-Rosei, E., Muiesan, M. L. and Rizzoni, D. (1996) Cardiovascular structural alterations in hypertension: Effect of treatment. Clin Exp Hypertens, 18, pp. 513-522.
18. Izzard, A. S., Rizzoni, D., Agabiti-Rosei, E. and Heagerty, A. M. (2005) Small artery structure and hypertension: Adaptive changes and target organ damage. J Hypertens, 23, pp. 247-250.
19. Bang, L. M., Chapman, T. M. and Goa, K. L. (2003) Lercanidipine: A review of its efficacy in the management of hypertension. Drugs, 63, pp. 2449-2472.
20. Wirtz, S. and Herzig, S. (2004) Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. Br J Pharmacol, 142, pp. 275-284.
21. 2+ channel antagonist lercanidipine in human cardiovascular tissue. Clin Exp Pharmacol Physiol, 32, pp. 708-713.
22. Parati, G., Casadei, R., Groppelli, A., Rienzo, M. Di and Mancia, G. (1989) Comparison of finger and intra-arterial blood pressure monitoring at rest and during laboratory testing. Hypertension, 13, pp. 647-655.
23. Folkow, B., Gribby, G. and Thulesius, O. (1958) Adaptative structural changes of the vascular walls in hypertension and their relation to the control of the peripheral resistance. Acta Physiol Scand, 44, pp. 255-272.
24. Thijssen, D. H. J., Bleeker, M. W. P., Smits, P. and Hopman, M. T. (2005) Reproducibility of blood flow and post-occlusive reactive hyperaemia as measured by venous occlusion plethysmography. Clin Sci, 108, pp. 151-156.
25. Folkow, B., Hansson, L. and Sivertsson, R. (1983) Structural factors in the pathogenesis of hypertension. Handbook of hypertension, pp. 133-150. Elsevier, Amsterdam
26. Mulvany, M., Hansen, P. K. and Aalkjaer, C. (1978) Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media and an increased number of smooth muscle cell layers. Circ Res, 43, pp. 854-864.
27. Jern, S. (1987) Reversibility of vascular hypertrophy in pharmacologically treated patients. J Cardiovasc Pharmacol, 10, pp. s112-s115.
28. Gretzer, I., Duner, H. and Lagerback, B. (1985) Haemodynamic effects of pindolol in essential hypertension with special reference to resistance vessels in the forearm during maximal vasodilatation. J Hypertens, 3, pp. s215-s217.
29. Taddei, S., Virdis, A., Ghiadoni, L., Versari, D., Salvetti, G. and Magagna, A. (2003) Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension, 41, pp. 950-955.
30. Tomlinson, B. and Benzie, I. F. (2003) Antioxidant effect of lercanidipine. Hypertension, 42, pp. e10-e11.
31. Martinez, M. L., Lopes, L. F., Coelho, E. B., Nobre, F., Rocha, J. B. and Gerlach, R. F. (2006) Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol, 47, pp. 117-122.
32. Brunner, H., Cockcroft, J. R., Deanfield, J., Donald, A., Ferrannini, E. and Halcox, J. (2005) Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. J Hypertens, 23, pp. 233-246.
33. Schulze, P. C. and Lee, R. T. (2005) Oxidative stress and atherosclerosis. Curr Atheroscler Rep, 7, pp. 242-248.
34. Canavesi, M., Baldini, N., Leonardi, A., Sironi, G., Bellosta, S. and Bernini, F. (2004) In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol, 44, pp. 416-422.
35. Grassi, G., Seravalle, G., Turri, C., Bolla, G. and Mancia, G. (2003) Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension, 41, pp. 558-562.
36. Grassi, G. (1998) Role of the sympathetic nervous system in human hypertension. J Hypertens, 16, pp. 1979-1987.
37. Grassi, G., Seravalle, G., Dell'Oro, R., Trevano, F. Q., Bombelli, M. and Scopelliti, F. (2003) Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens, 21, pp. 1761-1769.
38. Agabiti-Rosei, E., Muiesan, M. L., Rizzoni, D., Romanelli, G., Beschi, M. and Castellano, M. (1991) Regression of cardiovascular structural changes after long-term antihypertensive treatment with the calcium antagonist nitrendipine. J Cardiovasc Pharmacol, 18, pp. s5-s9.